TY - JOUR
T1 - Expression of CD44 splicing isoforms in lung cancers
T2 - Dominant expression of CD44v8-10 in non-small cell lung carcinomas
AU - Sasaki, J. I.Ichiro
AU - Tanabe, Kenneth K.
AU - Takahashi, Kazuhisa
AU - Okamoto, Isamu
AU - Fujimoto, Hisao
AU - Matsumoto, Mitsuhiro
AU - Suga, Moritaka
AU - Ando, Masayuki
AU - Saya, Hideyuki
PY - 1998/3
Y1 - 1998/3
N2 - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.
AB - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.
UR - https://www.scopus.com/pages/publications/0031882175
UR - https://www.scopus.com/pages/publications/0031882175#tab=citedBy
U2 - 10.3892/ijo.12.3.525
DO - 10.3892/ijo.12.3.525
M3 - Article
C2 - 9472088
AN - SCOPUS:0031882175
SN - 1019-6439
VL - 12
SP - 525
EP - 533
JO - International journal of oncology
JF - International journal of oncology
IS - 3
ER -
